• Skip to primary navigation
  • Skip to main content
BC

biochimica clinica

etdal

INDICE AUTORI

October 10, 2024 by etdal

Filed Under: SS1 56° SIBioC Congress

Epidemia da vaiolo delle scimmie (mpox): proattività, senza panico

September 20, 2024 by etdal

Filed Under: N. 4 December 2024 305-385 Tagged With: monkeypox; mpox; epidemic

Il Laboratorio clinico delle immunopatologie: tra diagnostica e comunicazione scientifica

September 20, 2024 by etdal

Filed Under: N. 4 December 2024 305-385

La Tossicologia Clinica incontra la Tossicologia Forense nella Medicina di Laboratorio

September 20, 2024 by etdal

Filed Under: N. 4 December 2024 305-385

Dalle colture cellulari bidimensionali agli organoidi: il progresso nel campo delle patologie neoplastiche

September 20, 2024 by etdal

Filed Under: N. 4 December 2024 305-385 Tagged With: culture cellulari, medicina di precisione, organoidi

Health Technology Assessment per il Point of Care Testing e il concetto di Value- Based Healthcare nei laboratori clinici

September 20, 2024 by etdal

Filed Under: N. 4 December 2024 305-385 Tagged With: Health Technology Assessment, Point of Care Testing, Value Based Healthcare

Titration of galenic preparations of cannabis oil: the experience of the Levante Ligure reference laboratory

September 20, 2024 by etdal

Filed Under: N. 4 December 2024 305-385 Tagged With: cannabis oil, galenic preparation, medical cannabis

Assessment of per and polyfluoroalkyl substances (pfas) in maternal blood

September 20, 2024 by etdal

Filed Under: N. 4 December 2024 305-385 Tagged With: liquid chromatography-mass spectrometry, maternal blood, PFAS

Assessing the suitability of non-molecular methods for screening beta-thalassemia carriers: clinical insights from laboratory data

September 20, 2024 by etdal

Filed Under: N. 4 December 2024 305-385 Tagged With: hematology analyzer, hemoglobinopathies, thalassemia

Valutazione di un pannello di biomarcatori come surrogato del recettore solubile dell’attivatore del plasminogeno di tipo urochinasico (suPAR) per l’indicazione al trattamento con anakinra in pazienti COVID-19

September 20, 2024 by etdal

Filed Under: N. 4 December 2024 305-385 Tagged With: anakinra, COVID-19, suPAR

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 106
  • Go to Next Page »